Time course and predictors of symptoms after primary prostate cancer therapy.
about
Low-dose rate brachytherapy for men with localized prostate cancerAcceptability and preliminary feasibility of an internet/CD-ROM-based education and decision program for early-stage prostate cancer patients: randomized pilot studyChallenges to treat hypogonadism in prostate cancer patients: implications for endocrinologists, urologists and radiotherapistsChronic radiation proctitis: tricks to prevent and treatEndoscopic and non-endoscopic approaches for the management of radiation-induced rectal bleedingGenome-wide association study to identify single nucleotide polymorphisms (SNPs) associated with the development of erectile dysfunction in African-American men after radiotherapy for prostate cancerQuality of life and satisfaction with information after radical prostatectomy, radical external beam radiotherapy and postoperative radiotherapy: a long-term follow-up study.Intra-operative 3D guidance and edema detection in prostate brachytherapy using a non-isocentric C-armA reference set of health utilities for long-term survivors of prostate cancer: population-based data from Ontario, Canada.Data pooling and analysis to build a preliminary item bank: an example using bowel function in prostate cancer.ProsCan for Couples: randomised controlled trial of a couples-based sexuality intervention for men with localised prostate cancer who receive radical prostatectomy.Race, healthcare access and physician trust among prostate cancer patientsRecommended patient-reported core set of symptoms to measure in prostate cancer treatment trials.Evidence-based guideline recommendations on low-dose rate brachytherapy in patients with low- or intermediate-risk prostate cancer.Low-dose rate brachytherapy for patients with low- or intermediate-risk prostate cancer: A systematic review.Diabetes mellitus and health-related quality of life in prostate cancer: 5-year results from the Prostate Cancer Outcomes Study.Long-term (10-year) gastrointestinal and genitourinary toxicity after treatment with external beam radiotherapy, radical prostatectomy, or brachytherapy for prostate cancer.Guiding prostate cancer treatment choices. Early detection means more options for more men.Trajectories and predictors of symptom occurrence, severity, and distress in prostate cancer patients undergoing radiation therapyEstimating the risk of long-term erectile, urinary and bowel symptoms resulting from prostate cancer treatment.Health-related quality of life and satisfaction with care among older men treated for prostate cancer with either radical prostatectomy or external beam radiation therapy.Localized External Beam Radiation Therapy (EBRT) to the Pelvis Induces Systemic IL-1Beta and TNF-Alpha Production: Role of the TNF-Alpha Signaling in EBRT-Induced Fatigue.A 2-stage genome-wide association study to identify single nucleotide polymorphisms associated with development of erectile dysfunction following radiation therapy for prostate cancer.Supportive care needs of men living with prostate cancer in England: a survey.Severity of cardiovascular disease and health-related quality of life in men with prostate cancer: a longitudinal analysis from CaPSUREDoes Race Influence Health-related Quality of Life and Toxicity Following Proton Therapy for Prostate Cancer?Measuring health-related quality of life consequences from primary treatment for early-stage prostate cancer.Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer.Prediction of erectile function following treatment for prostate cancer.Brachytherapy in the therapy of prostate cancer - an interesting choiceRadiogenomics: using genetics to identify cancer patients at risk for development of adverse effects following radiotherapy."Pelvic radiation disease": new understanding and new solutions for a new disease in the era of cancer survivorship.Choice between prostatectomy and radiotherapy when men are eligible for both: a randomized controlled trial of usual care vs decision aid.Development of clinical models for predicting erectile function after localized prostate cancer treatment.Long-term quality of life after definitive treatment for prostate cancer: patient-reported outcomes in the second posttreatment decade.Exercise does not counteract the effects of a "westernized" diet on prostate cancer xenografts.Robot-assisted laparoscopic radical prostatectomy after previous open transvesical adenomectomy.Factors associated with current and severe physical side-effects after prostate cancer treatment: What men report.Quality of life after prostate cancer treatments in patients comparable at baseline.Acute Urinary Morbidity Following Stereotactic Body Radiation Therapy for Prostate Cancer with Prophylactic Alpha-Adrenergic Antagonist and Urethral Dose Reduction.
P2860
Q24235544-B72D60EB-BF5C-48EA-9974-346DD3ED3FC3Q24633980-9F2352A8-6168-4EE2-B9E0-E4B918E83128Q26773738-8E7D4E54-50D5-4161-A3CE-FD7AD527420FQ26801205-A81CC6F4-488B-46D6-B4E4-3E37872851E7Q28076526-56834B50-AC0B-419A-B17D-D8ADB44C7B17Q28943357-95311048-03F5-4523-83F7-4451B34A84A8Q30209897-C0BD5E7E-DB6C-4FFF-A37A-458D491D9972Q30395258-C6F9F699-0FA4-4FED-BD90-66AB11EC85B1Q30613075-F08A9164-4BAB-4AD8-B699-D5E7D0179C6BQ30988028-88D6DE5B-DBBC-435B-9E70-6FE54EF59C1CQ33358563-A6EE3216-7211-4818-9CA4-299F7522BCD4Q33610509-1C4D9CF7-4A10-48F8-AFDC-803974A0D846Q34315605-2152B53D-706D-41EC-ADAF-722FF4CB6FD8Q34795596-FE72DF65-84DF-47B4-9DC9-4FB2AF84220DQ35079338-21F712BA-8AF2-44E8-A1D6-8F8DC2AA5E5BQ35797092-BAF8D4AB-F24D-4AC0-BF08-335E93EC04F9Q35936700-87E70741-4A32-4E6E-834B-9B70343B88F8Q36102967-CE7D76A3-3E33-42FF-B10C-96786C49DC2FQ36296032-7DCC7437-9525-4D41-9AE8-27BCFF1CBAF7Q36364403-B8EA96F5-603E-4120-9309-4E8A24319F62Q36462112-BB067769-B630-42D8-A477-2AC615C5DFB9Q36522593-B3AADE9D-98CE-47E3-80F0-51138C13EA63Q36740528-A2E20804-2BFD-4AD9-BC02-BC72D27017BEQ36740627-AC84FACD-5FE3-49DB-BDED-460FF18A25B8Q36800371-E226ED72-BBA4-4B0B-B618-C141C1942E1CQ36925871-8AC29EF1-CF7A-47E4-A625-302D622E50BBQ37033117-F20DEF2C-BA17-4EBC-9BF8-4AAD66840858Q37139334-0BFE08C0-8976-45B8-80F5-98932848ACFEQ37318611-CEC9D747-18A9-4241-B63E-1051E133F492Q37601857-3375F0A9-93EC-4CA6-B31C-785E886F9F5DQ37624254-4BDAE5F1-7DB7-4860-8B1C-B78109D4F1A0Q37824328-F083B23D-2F11-468C-8A30-433C7640C92FQ38033742-A83453B6-5742-4471-86BB-99B35E2990C2Q38233280-72B11779-E5C6-4066-BCC5-1488E5C829A2Q38754823-532C7037-BD1C-4116-B8CD-7A0DE37211F9Q39158438-10A45D0E-B87F-4270-996E-4EDF17BE9DD9Q39381140-59D37F7D-5B47-43FA-943E-DE1F2204FD0FQ40547127-2E1F9E62-923F-43F5-9D36-C008D4AAAF3FQ40844364-0D9D4320-36C1-465C-81CF-F2AC2E5B55FDQ41821780-4504F373-9B78-4A73-BF1F-82F7263C2E35
P2860
Time course and predictors of symptoms after primary prostate cancer therapy.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Time course and predictors of symptoms after primary prostate cancer therapy.
@en
Time course and predictors of symptoms after primary prostate cancer therapy.
@nl
type
label
Time course and predictors of symptoms after primary prostate cancer therapy.
@en
Time course and predictors of symptoms after primary prostate cancer therapy.
@nl
prefLabel
Time course and predictors of symptoms after primary prostate cancer therapy.
@en
Time course and predictors of symptoms after primary prostate cancer therapy.
@nl
P2093
P356
P1476
Time course and predictors of symptoms after primary prostate cancer therapy.
@en
P2093
Anthony V D'Amico
Clair J Beard
Irving Kaplan
James A Talcott
Judithy Manola
Michael P O'Leary
Ronald C Chen
Sonya P Mitchell
P304
P356
10.1200/JCO.2003.01.199
P407
P577
2003-11-01T00:00:00Z